EIB funding for Minoryx' rare genetic diseases research

1 November 2020
european_commission_large

The European Investment Bank (EIB), backed by the European Fund for Strategic Investments (EFSI), will provide 25 million euros ($29 million) of financing to Minoryx Therapeutics, a Spanish biotech company specializing in the advancement of treatments for rare central nervous system disorders.

The newly-available funding will thus benefit Minoryx' research and development activities in orphan genetic diseases for which there are currently no approved drugs available.

Just over a month ago, Minoryx signed a deal with China’s Sperogenix Therapeutics exclusive rights to develop and sell leriglitazone, Minoryx' brain penetrating disease-modifying PPAR-γ agonist the therapy, in China, Hong Kong and Macau, for X-linked adrenoleukodystrophy (X-ALD). This deal is worth a potential $78 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology